plus qescor's actar gel is not the same as acth. f someone did come out with some kind of generic competition, remember. actar is approved for 19 different indications. somebody trying to challenge them would have to go through 19 clinical trials. that's a huge barrier to entry right there. i don't want to be too hard on the shorts here. shorts bring a lot of attention to different situations. a lot of the shorts are convinced that qescor must be some kind of a scam. i can kind of sort of see where they're coming from, even if i think they're wrong. qescor bought the rights to this gel for just $100,000 back in 2001. so people think, who would ever sell it to them? can't be worth much. but actar is expected to do 480 million in sales this year, as much as 2 billion in peak sales. the shorts in the low price qescor paid, they seat company's big sales force and they assume actar gel is nothing more than pharmaceutical grade snake oil. i think that's wrong. you see, something a big change between 2001 when qescor bought actar for a song

a product called actar gel. out's not a new drug that's untried or untested.rom 50 cents to 52 dollars on the strength of this single product sounds crazy. that attracts the bears. it makes sense. it's been approved for 19 indications. in other words they have one drug. some people consider it a wonderdrug. it might as well be 19 different drugs. it treats 19 diseases. multiple sclerosis flares, infantile spasms and nephrotic syndrome, a kidney syndrome. the gel is given to doctors who use it to treat the 19 conditions. the company is testing it on more new indications so it could gain fda approval to treat more diseases. seems like a terrific story to me. what do people hate about it? there have always been short sellers betting against this one. there still are. 44% of the outstanding shares. that's a figure that says people think this is a joke. for the most part, the shorts were getting their heads handed to them until july. when a bunch of websites started to report rumors about potential competition. that's how it went that far in less than a month. if t

gel for just $100,000 back in 2001. people think, come on, who would sell it to them? can't be worth much. but actarexpected to do $480 million in sales this year. as much as $2 billion in peak sales. the price they paid, they see the company's big sales force, and they assume acthar gel is nothing more than pharmaceutical grade snake oil. that's wrong. a big change between 2001 when questcore bought it for a song and now selling it for high prices. in 2010, the gel was granted orphan drug status by the fda. these drugs treat diseases that afflict small groups of people. so governments give the companies that make these drugs lots of extra incentives to make it worthwhile. because it is an orphan, they can charge an arm and a leg for it. there is no alternative. a single prescription can cost up to $200,000. then earlier this week, we got the validation for the bulls, not bears. it was the only kick in the teeth for the bears. many short sellers believe it is a scam. questcore said the u.s. government made them eligible for significantly lower medicaid reimbursement on achtar. in the past qcor didn'